Demographic characteristics for InterLymph case-control studies with exposure data by CLL/control status
| . | . | . | CLL cases genotyped . | Controls genotyped . | Male CLL cases . | Male controls . | Age cases . | Age controls . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study . | Location . | Study design . | N . | Column % . | N . | Column % . | N . | Row % . | N . | Row % . | Median (range) . | Median (range) . |
| MAYO | Iowa, Minnesota, Wisconsin | Clinic-based | 580 | 38.7 | 688 | 28.0 | 404 | 69.7 | 394 | 57.3 | 62 (27-88) | 60 (20-93) |
| SCALE | Denmark, Sweden | Population-based | 357 | 23.8 | 291 | 11.8 | 236 | 66.1 | 168 | 57.7 | 63 (30-74) | 64 (20-75) |
| UCSF2 | San Francisco, CA | Population-based | 235 | 15.7 | 673 | 27.4% | 151 | 64.3 | 387 | 57.5 | 64 (30-84) | 63 (20-84) |
| EPILYMPH | Spain, France, Germany, Italy, Ireland, Czech Republic | Population-based (Italy, Germany), otherwise hospital-based | 158 | 10.5 | 211 | 8.6 | 104 | 65.8 | 114 | 54.0 | 64 (30-87) | 62 (19-85) |
| NCI-SEER | Detroit, MI; Iowa; Los Angeles, CA; Seattle, WA | Population-based | 86 | 5.7 | 270 | 11.0 | 51 | 59.3 | 146 | 54.1 | 62 (38-74) | 59 (21-74) |
| ENGELA | Bordeaux, Brest, Caen, Lille, Nantes, Toulouse (France) | Hospital-based | 44 | 2.9 | 63 | 2.6 | 29 | 65.9 | 41 | 65.1 | 62 (37-74) | 57 (20-75) |
| BC | Vancouver, Victoria, British Columbia (Canada) | Population-based | 26 | 1.7 | 109 | 4.4 | 20 | 76.9 | 61 | 56.0 | 65 (50-80) | 62 (24-80) |
| NSW | New South Wales, Australian Capital Territory (Australia) | Population-based | 13 | 0.9 | 154 | 6.3 | 8 | 61.5 | 93 | 60.4 | 64 (42-73) | 58 (22-73) |
| Total | 1499 | 100 | 2459 | 100 | 1003 | 66.9 | 1404 | 57.1 | 63 (27-88) | 61 (19-93) | ||
| . | . | . | CLL cases genotyped . | Controls genotyped . | Male CLL cases . | Male controls . | Age cases . | Age controls . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study . | Location . | Study design . | N . | Column % . | N . | Column % . | N . | Row % . | N . | Row % . | Median (range) . | Median (range) . |
| MAYO | Iowa, Minnesota, Wisconsin | Clinic-based | 580 | 38.7 | 688 | 28.0 | 404 | 69.7 | 394 | 57.3 | 62 (27-88) | 60 (20-93) |
| SCALE | Denmark, Sweden | Population-based | 357 | 23.8 | 291 | 11.8 | 236 | 66.1 | 168 | 57.7 | 63 (30-74) | 64 (20-75) |
| UCSF2 | San Francisco, CA | Population-based | 235 | 15.7 | 673 | 27.4% | 151 | 64.3 | 387 | 57.5 | 64 (30-84) | 63 (20-84) |
| EPILYMPH | Spain, France, Germany, Italy, Ireland, Czech Republic | Population-based (Italy, Germany), otherwise hospital-based | 158 | 10.5 | 211 | 8.6 | 104 | 65.8 | 114 | 54.0 | 64 (30-87) | 62 (19-85) |
| NCI-SEER | Detroit, MI; Iowa; Los Angeles, CA; Seattle, WA | Population-based | 86 | 5.7 | 270 | 11.0 | 51 | 59.3 | 146 | 54.1 | 62 (38-74) | 59 (21-74) |
| ENGELA | Bordeaux, Brest, Caen, Lille, Nantes, Toulouse (France) | Hospital-based | 44 | 2.9 | 63 | 2.6 | 29 | 65.9 | 41 | 65.1 | 62 (37-74) | 57 (20-75) |
| BC | Vancouver, Victoria, British Columbia (Canada) | Population-based | 26 | 1.7 | 109 | 4.4 | 20 | 76.9 | 61 | 56.0 | 65 (50-80) | 62 (24-80) |
| NSW | New South Wales, Australian Capital Territory (Australia) | Population-based | 13 | 0.9 | 154 | 6.3 | 8 | 61.5 | 93 | 60.4 | 64 (42-73) | 58 (22-73) |
| Total | 1499 | 100 | 2459 | 100 | 1003 | 66.9 | 1404 | 57.1 | 63 (27-88) | 61 (19-93) | ||
BC, British Columbia Non-Hodgkin Lymphoma study; ENGELA, Environmental and Genetic Risks Factors Study in Adult Lymphoma; EPILYMPH, European multi-center case–control study; MAYO, Mayo Clinic; NSW, New South Wales non-Hodgkin Lymphoma study; SCALE, Scandinavian Lymphoma Etiology study; UCSF2, University of California San Diego Molecular Epidemiology of non-Hodgkin Lymphoma study.